Pembrolizumab improves outcomes in high-risk bladder cancer
WEB5 days ago · NCI Press Office. 240-760-6600. Adjuvant pembrolizumab helps people with muscle-invasive bladder cancer remain cancer-free longer than observation alone. Credit: Terese Winslow/National Cancer Institute. Results from a large clinical trial show that treatment with an immunotherapy drug may nearly …
Immunotherapy after surgery helps people with high-risk bladder cancer ...
WEB5 days ago · They randomly assigned 702 patients with high-risk, muscle-invasive bladder cancer who had undergone bladder-removal surgery to receive adjuvant therapy with pembrolizumab every three weeks for a year, or to observation for the same period of time.
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced …
WEBMar 6, 2024 · Treatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma,...
Adjuvant Pembrolizumab: A New Option for High-Risk Muscle …
WEBMar 25, 2024 · Adjuvant use of the PD-1 inhibitor pembrolizumab achieved a statistically significant and clinically meaningful improvement in disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma vs observation after surgical resection, according to an interim analysis of the phase III AMBASSADOR trial …
Disitamab vedotin/pembrolizumab shows promise in HER2 …
WEB3 days ago · The combination of disitamab vedotin and pembrolizumab (Keytruda) demonstrated encouraging preliminary activity with a manageable safety profile in treatment-naïve patients with HER2-expressing, locally advanced or metastatic urothelial carcinoma, according to data from cohort C of the phase 2 RC48G001 trial (NCT04879329). Matthew D. Galsky, MD.
Padcev and Keytruda Double Bladder Cancer Survival - NCI
WEBNov 30, 2023 · UPDATE: On December 15, 2023, FDA approved enfortumab vedotin (Padcev) in combination with pembrolizumab (Keytruda) for people with bladder cancer that has spread to other parts of the body or cannot be removed surgically.
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive …
WEBSep 14, 2024 · Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive uro... Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in …
WEBApr 3, 2023 · KEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab …
WEBDec 15, 2023 · “Advanced bladder cancer is a common cause of cancer-related death. The overall survival benefit seen in the EV-302 trial demonstrates the potential for PADCEV in combination with pembrolizumab to impact first-line treatment of patients with locally advanced or metastatic urothelial carcinoma.
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder …
WEBMay 10, 2024 · Pembrolizumab monotherapy showed antitumour activity and manageable toxicity in patients with BCG-unresponsive high-risk Ta or T1 bladder cancer without carcinoma in situ and could potentially be a suitable treatment option for patients who decline or are ineligible for radical cystectomy.
Skip to content